ProCE Banner Activity

Expert Discussions: Novel Agents Targeting Residual Inflammatory Risk in ASCVD and CKD

Podcast Episodes

Join us for this podcast episode with cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD. 

Released: August 27, 2024

Expiration: August 26, 2025

Share

Faculty

Erin Michos

Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Professor of Medicine
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Co Center-Director, IMPACT Center at JHU
(Improving Participation Among Diverse Populations in Cardiovascular Clinical Trials)
Co-Editor in Chief
American Journal of Preventive Cardiology
Baltimore, Maryland

Mark J. Sarnak

Mark J. Sarnak, MD, MS

Chief, Division of Nephrology
Tufts Medical Center
Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC in partnership with American Kidney Fund

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

American Kidney Fund

ProCE Banner

Disclosure

Primary Author

Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Professor of Medicine
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Co Center-Director, IMPACT Center at JHU
(Improving Participation Among Diverse Populations in Cardiovascular Clinical Trials)
Co-Editor in Chief
American Journal of Preventive Cardiology
Baltimore, Maryland

Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC: consultant/advisor/speaker: Amgen, Arrowhead, AstraZeneca, Boehringer Ingelheim, Edwards Lifescience, Ionis, Lilly, Medtronic, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer.

Mark J. Sarnak, MD, MS

Chief, Division of Nephrology
Tufts Medical Center
Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Mark J. Sarnak, MD, MS: consultant/advisor/speaker: Akebia, Boehringer Ingelheim.